Viking Therapeutics's total assets for Q3 2025 were $739.41M, a decrease of -10.68% from the previous quarter. VKTX total liabilities were $26.39M for the fiscal quarter, a -18.54% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.